Market Cap 441.22M
Revenue (ttm) 8.78M
Net Income (ttm) -104.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,192.48%
Debt to Equity Ratio 0.00
Volume 1,044,100
Avg Vol 823,952
Day's Range N/A - N/A
Shares Out 52.97M
Stochastic %K 4%
Beta 0.95
Analysts Strong Sell
Price Target $23.88

Latest News on STOK

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Feb 16, 2025, 2:23 PM EST - 6 days ago

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer


Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 7, 2024, 4:03 AM EDT - 6 months ago

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome


Stoke Therapeutics Announces Proposed Public Offering

Mar 26, 2024, 4:07 PM EDT - 11 months ago

Stoke Therapeutics Announces Proposed Public Offering


Stoke Therapeutics Is Unable To Derisk Its Platform

Sep 10, 2023, 5:08 PM EDT - 1 year ago

Stoke Therapeutics Is Unable To Derisk Its Platform


Stoke Therapeutics Looks Unfairly Valued

Feb 12, 2023, 5:17 AM EST - 2 years ago

Stoke Therapeutics Looks Unfairly Valued